Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.







16.06.2024, 2077 Zeichen

Marinomed: Marinomed Biotech AG expands its license regarding the distribution of Marinomed’s Carragelose products with an existing partner and leading Consumer Health Care market player. The agreement provides for the marketing and distribution of Carragelose products in several EU-countries and some non-EU countries pending any required regulatory approvals. Under the terms of the agreement and depending on the achievement of specified regulatory and commercial targets, Marinomed is eligible to receive milestone payments. “Broadening our license with a leading Consumer Health Company is a huge success and validation of our Carragelose product line”, Andreas Grassauer, CEO of Marinomed, comments. “Expanding to additional countries is another significant step for our business, and we are looking forward to realizing the full potential of our products.”
Marinomed Biotech: weekly performance: 0.38%

Pierer Mobility: In the current financial year, momentum in PIERER Mobility's core motorbike markets in the USA and Europe has slowed significantly. For the 2024 financial year, the Executive Board expects a decline in sales of 10% to 15% for both the motorcycles and bicycle divisions due to the current market developments. In the Motorcycles segment, the Executive Board assumes that the cost savings introduced in the current financial year will be able to compensate for the negative effects of declining sales to such an extent that a balanced to slightly positive EBIT can be generated. The development of existing dealers and the further expansion of the dealer network to support the brand strategy will be key issues in 2024. In the Bicycle division, however, the Executive Board anticipates a significantly negative EBIT of €-110 to €-130 million for the 2024 financial year, which is essentially due to extraordinary impairment and restructuring requirements. The restructuring of the Bicycle division is therefore complete. 
Pierer Mobility: weekly performance: -2.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/06/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #699: DAX ändert Eröffnung vs. ATX bleibt wie gehabt, Tausch bei der Addiko Bank, Einbrecher blieben aus


 

Bildnachweis

1. Pierer Mobility - KTM Product portfolio   >> Öffnen auf photaq.com



Aktien auf dem Radar:Warimpex, CA Immo, Bawag, Austriacard Holdings AG, Lenzing, Amag, Telekom Austria, DO&CO, Rosenbauer, Cleen Energy, S Immo, Wiener Privatbank, Oberbank AG Stamm, Marinomed Biotech, Agrana, Erste Group, EVN, Flughafen Wien, Immofinanz, Mayr-Melnhof, Österreichische Post, Uniqa, VIG, Wienerberger, Verizon, RWE, Bayer, Deutsche Bank, Infineon, Deutsche Telekom, Sartorius.


Random Partner

VIG
Die Vienna Insurance Group (VIG) ist mit rund 50 Konzerngesellschaften und mehr als 25.000 Mitarbeitern in 30 Ländern aktiv. Bereits seit 1994 notiert die VIG an der Wiener Börse und zählt heute zu den Top-Unternehmen im Segment “prime market“ und weist eine attraktive Dividendenpolitik auf.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner